Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2016 25
2017 44
2018 46
2019 43
2020 30
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

162 results
Results by year
Filters applied: . Clear all
Page 1
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD. Daly MB, et al. J Natl Compr Canc Netw. 2020 Apr;18(4):380-391. doi: 10.6004/jnccn.2020.0017. J Natl Compr Canc Netw. 2020. PMID: 32259785
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndrom …
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic te …
Genetic and Genomic Advances in Breast Cancer Diagnosis and Treatment.
Walker-Smith TL, Peck J. Walker-Smith TL, et al. Nurs Womens Health. 2019 Dec;23(6):518-525. doi: 10.1016/j.nwh.2019.09.003. Epub 2019 Oct 25. Nurs Womens Health. 2019. PMID: 31669147 Review.
As more innovative and advanced treatment options emerge, women's health outcomes and survival rates may improve. Nursing professionals in primary care and women's health specialties must be aware of the latest options for testing, referrals, and treatment modalitie …
As more innovative and advanced treatment options emerge, women's health outcomes and survival rates may improve. Nursing professiona …
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. Konstantinopoulos PA, et al. J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27. J Clin Oncol. 2020. PMID: 31986064
Genetic evaluations should be conducted in conjunction with health care providers familiar with the diagnosis and management of hereditary cancer. First- or second-degree blood relatives of a patient with ovarian cancer with a known germline pathogenic cancer suscep …
Genetic evaluations should be conducted in conjunction with health care providers familiar with the diagnosis and management of hereditar
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. US Preventive Services Task Force, et al. JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987. JAMA. 2019. PMID: 31429903
Regardless of family or personal history, the USPSTF found adequate evidence that the overall harms of risk assessment, genetic counseling, genetic testing, and interventions are small to moderate. CONCLUSIONS AND RECOMMENDATION: The USPSTF recommends that primary care cli …
Regardless of family or personal history, the USPSTF found adequate evidence that the overall harms of risk assessment, genetic couns …
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Nelson HD, et al. JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430. JAMA. 2019. PMID: 31429902
Twenty studies (n = 4322) showed that breast cancer worry and anxiety were higher after testing for women with positive results and lower for others; understanding of risk was higher after testing. In 8 RCTs (n = 54 651), tamoxifen (relative risk [RR], 0.69 [95% CI, 0.59-0 …
Twenty studies (n = 4322) showed that breast cancer worry and anxiety were higher after testing for women with positive results and lower fo …
Universal Genetic Testing for All Breast Cancer Patients.
Copur MS. Copur MS. Oncology (Williston Park). 2019 Aug 23;33(8):683731. Oncology (Williston Park). 2019. PMID: 31469901 Free article.
The US Preventive Services Task Force and the National Comprehensive Cancer Network have recommended that women with a family history of breast, ovarian, and certain other cancers consider BRCA1/2 testing. Discovery of additional genes that increase breast cancer risk, cou …
The US Preventive Services Task Force and the National Comprehensive Cancer Network have recommended that women with a family history …
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. Daly MB, et al. J Natl Compr Canc Netw. 2017 Jan;15(1):9-20. doi: 10.6004/jnccn.2017.0003. J Natl Compr Canc Netw. 2017. PMID: 28040716
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagno …
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendatio …
MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
Rayes N, Bowen DJ, Coffin T, Nebgen D, Peterson C, Munsell MF, Gavin K, Lechner R, Crase J, Polinsky D, Romero I, Blank SV, Levine DA, Norquist BM, Swisher EM, Lu KH. Rayes N, et al. BMC Cancer. 2019 Jul 2;19(1):648. doi: 10.1186/s12885-019-5868-x. BMC Cancer. 2019. PMID: 31266460 Free PMC article. Clinical Trial.
METHODS: 3000 women nationwide will undergo genetic testing for 19 hereditary cancer genes. This is a randomized four-arm non-inferiority study with equal randomization. ...
METHODS: 3000 women nationwide will undergo genetic testing for 19 hereditary cancer genes. This is a randomized four-arm non-inferio …
The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).
Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, Tsuda H, Watanabe Y, Yoshihara K, Sugiyama T. Enomoto T, et al. Int J Gynecol Cancer. 2019 Jul;29(6):1043-1049. doi: 10.1136/ijgc-2019-000384. Int J Gynecol Cancer. 2019. PMID: 31263023
INTRODUCTION: BRCA gene mutations are associated with hereditary ovarian cancer. BRCA plays a key role in genome integrity, and mutations result in an increased risk for ovarian cancer. ...Most patients were satisfied with pre-test counseling, irrespective of the service p …
INTRODUCTION: BRCA gene mutations are associated with hereditary ovarian cancer. BRCA plays a key role in genome integrity, and mutat …
162 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page